Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.7146
- Book/Share 20.7794
- PB 5.5818
- Debt/Equity 0.798
- CurrentRatio 1.6612
- ROIC 0.191
- MktCap 289393167113.0
- FreeCF/Share 5.2238
- PFCF 22.1774
- PE 15.2053
- Debt/Assets 0.3194
- DivYield 0.0283
- ROE 0.3895
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MRK | Wolfe Research | Peer Perform | Outperform | -- | $135 | Jan. 8, 2026 |
| Upgrade | MRK | BMO Capital Markets | Market Perform | Outperform | -- | $130 | Dec. 18, 2025 |
| Upgrade | MRK | Wells Fargo | Equal Weight | Overweight | -- | $125 | Nov. 24, 2025 |
| Initiation | MRK | Scotiabank | -- | Sector Outperform | -- | $105 | Nov. 13, 2025 |
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
News
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Read More
MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance disappoints.
Read More
Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
2 Pharma Stocks React to Quarterly Results, Guidance
Published: February 03, 2026 by: Schaeffers Research
Sentiment: Negative
Pfizer Inc (NYSE:PFE) shares are down 3.2% to trade at $25.40 at last check, despite surpassing earnings and revenue expectations for the fourth quarter.
Read More
Merck shares dip as 2026 outlook misses Wall Street expectations
Published: February 03, 2026 by: Proactive Investors
Sentiment: Negative
Merck & Co Inc (NYSE:MRK, XETRA:6MK) shares fell 2% at Tuesday's opening bell after the drugmaker issued a 2026 outlook that came in below Wall Street expectations, overshadowing a fourth-quarter earnings and revenue beat. Merck forecast 2026 revenue of $65.5 billion to $67.0 billion, compared with analysts' estimates of $67.6 billion, and adjusted earnings of $5 to $5.15 per share versus expectations of $5.36.
Read More
Merck (MRK) Q4 Earnings and Revenues Beat Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.72 per share a year ago.
Read More
Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year
Published: February 03, 2026 by: Market Watch
Sentiment: Negative
Merck's stock falls as the full-year revenue and profit outlooks were below expectations.
Read More
Merck Expects Slower Earnings Growth As It Spends on Acquisitions
Published: February 03, 2026 by: WSJ
Sentiment: Neutral
Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.
Read More
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Published: February 03, 2026 by: CNBC
Sentiment: Neutral
Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But Merck posted a modest 2026 outlook that fell short of Wall Street's expectations, as the company prepares for a few drugs to lose patent protection later this year and face generic competition.
Read More
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results.
Read More
Market Indexes Bounce Back to Start a New Trading Week
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Improved Manufacturing data joined another strong tranche of Q4 earnings reports today.
Read More
Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year
Published: February 02, 2026 by: 24/7 Wall Street
Sentiment: Positive
Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Read More
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Merck's Non-Oncology Drugs Q4 Performance: What to Expect
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Neutral
MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.
Read More
What's Fueling The Rally In Merck Stock?
Published: January 28, 2026 by: Forbes
Sentiment: Positive
Merck (MRK)'s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence.
Read More
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
Read More
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative
Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death risk by 49% in high-risk melanoma.
Read More
Merck partners with global health coalition to develop affordable Ebola vaccine
Published: January 21, 2026 by: Reuters
Sentiment: Positive
Merck and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have partnered on a $30 million program to develop an updated version of the drugmaker's Ebola vaccine aimed at improving affordability and access for low- and middle-income countries.
Read More
Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Negative
Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.
Read More
3 “Forever Stocks” to Hold When the Market Won't Sit Still
Published: January 19, 2026 by: MarketBeat
Sentiment: Negative
With so much volatility in the market, it's a good time for investors to consider stocks that they can hold for the long haul. These compounders don't have to make up a large part of your portfolio, but they're good stocks to have for investors who like to step away from their screens.
Read More
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Read More
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Negative
MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.
Read More
Is Merck Stock A Trap At $110?
Published: January 15, 2026 by: Forbes
Sentiment: Neutral
Merck stock surged more than 10% in a month after management delivered a confidence shock on January 12th. They're now projecting that their next-generation drugs—treatments for cardiometabolic, respiratory, and infectious diseases—will yield $70 billion by the mid-2030s.
Read More
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.
Read More
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Published: January 09, 2026 by: WSJ
Sentiment: Positive
Revolution is developing drugs that target a molecular driver of cancers.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert Davis
- Employees 73000